Tropane compounds

1. A compound having the formula:

Where:

the 2-, 3-, 6-, or 7- positions are α or β;

the compounds are racemic or 1R- or 1S- configured;

X=O, NR 3 , NR 10 , N-L-Ch, CHR 3 , CHR 1 , CH 2 ,CHW 1 , CW 1 W 1 , CO, S, SO, SO 2 , NSO 2 R 3 , NSO 2 R 11 or CX 2 W, with the N, C, O or S atom being a member of the ring;

L is a linking moiety comprising a chain of atoms containing 2 to about 6 carbon atoms;

Ch is a tridentate or tetradentate chelating ligand that forms a neutral complex with technetium or rhenium;

Ar=Phenyl or 1-naphthyl or 2-naphthyl, unsubstituted or substituted with one or more group selected from: —H; —Br; —CI; —I; —F; —OH; —CH 3 ; —OCH 3 ; —CF 3 ; —NO 2 ; —NH 2 ; —CN; —NHCOCH 3 , —C(CH 3 ) 3 , —C(CH 2 )CH 3 , (CH 2 ) q CH 3 , where q=0-6; —COCH 3 ; OAc; alkyl; alkenyl; alkynyl; allyl; isopropyl; isobutyl; wherein each substitutent can be at the 2, 3 and/or 4 position of the ring;

W or X 2 =H, OH, OCH 3 , OAc, OCOR 4 , CH 3 , (CH 2 ) n CH 3 , R 4 ;

W 1 =H, Br, CI, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 ) n CH 3 , COCH 3 , or C(CH 3 ) 3 ;

R 3 =independently for each occurrence H, CH 3 , CH 2 Ar, (CH 2 ) n Ar, Ar, alkyl, alkenyl or alkynyl, cycloalkylmethyl, CH 2 CH=CHZ, (CH 2 ) n OH, (CH 2 ) n OR 4 , CH=CHZ; CH 2 J-Maleimide, CH 2 JN-Maleimide where J=CH 2 or O; (CH 2 ) n OCOCH 3 ; (CH 2 ) n OCOCH 2 OCH 3 ; (CH 2 ) n -morpholine; (CH 2 ) n -piperidine; (CH 2 ) n -piperazine;

R 4 =CH 3 , CH 2 CH 3 , alkyl, alkenyl, alkynyl, allyl, isopropyl, isobutyl;

R 5 =H, CH 3 , (CH 3 ) 2 , (CH 2 ) n SO 3 Q, alkyl, (alkyl) 2 , alkenyl, alkynyl, Ar, OCH 3 ;

Q=K + , Na + , Li + , Ca 2+ , NH 4 + , RNH 3 + , or other pharmaceutically acceptable salts;

R 10 =COR 4 , CH 2 OH, (CH 2 ) n OH, (CH 2 ) n OR 4 , (CH 2 ) n COOR 3 , (CH 2 ) n OCOR 3 ;

R 2 =R 3 , OR 3 , isopropyl, isobutyl, OCOR 4 , OCOR 5 , W 1 , CH 2 R 3 , OCOR 3 , NHR 3 , COR 3 , (CH 2 ) n COOR 3 ;

R 1 =H, (CH 2 ) n OH, (CH 2 ) n OR 4 , CR 3 =NOR 3 , CH=NR 3 ; COOR 8 , COR 8 , CONHR 8 , CONR 8 R 8 , CH 2 CH 3 , (CH 2 ) n CH 3 , CHCHR 9 , (CH 2 ) n CCR 9 , (CH 2 ) n COOR 8 , (CH 2 ) n OCOR 8 , OCOR 8 , C 3 HNOR 9 or C 2 N 2 OR 9 ;

R 8 =R 3 , Br, CI, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 ) n CH 3 ,

COCH 3 , or C(CH 3 ) 3 ; C(CH 3 ) 3 , C 10 H 7 or C 10 H 6 W 1 ;

R 9 =COOR 8 , CH 3 , (CH 2 ) n CH 3 , C 6 H 5 , C 6 H 4 Y, C 10 H 7 or C 10 H 6 W 1 ;

n=0-4;

m=0-4; and

Z=F, CI, I or Br;

wherein at least one of X, R 2 or R 1 comprises a COOR 3 group or a OCOR 3 group and wherein at least one R 3 group comprises an alkyl, cycloalkylmethyl, alkenyl or alkynyl group, said alkyl, cycloalkylmethyl, alkenyl or alkynyl group having from 10 to 20 carbon atoms.

2. The compound of claim 1 , wherein the R 2 substituent comprises the R 3 alkyl, cycloalkylmethyl, alkenyl or alkynyl group having from 10 to 20 carbon atoms.

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 .

4. A method of diagnosing a disease that affects monoamine transport comprising labeling a compound of claim 1 , administering the labeled compound to a patient, imaging the binding of the labeled compound in the patient, and comparing said imaged patient binding to a reference standard.

5. The method of claim 4 , wherein the reference standard is that of a normal human subject lacking a disease or disorder of the nervous system, such that the imaged patient binding can be determined to be similar or dissimilar to the binding of the normal human subject.

6. The method of claim 5 , wherein the method is used to diagnose a disease or disorder affecting the patient.

7. The method of claim 6 in which the disease or disorder is attention deficit hyperactivity disorder (ADHD); Parkinson's disease; cocaine addiction.